A deeply discounted valuation and rising volume accumulation contrast sharply with a pattern of persistent earnings misses and business quality metrics well below the minimum acceptable threshold, making the setup speculative and uninvestable despite the favorable headline risk/reward geometry.
Thesis pillars
- Quality Below Minimum Floor↓Deteriorating
- Extreme Valuation Discount↓Deteriorating
- Persistent Earnings Misses→Stable
- +1 more pillar — see the Why tab for full reasoning
AdaptHealth Corp. (AHCO) Stock Analysis
Recovery setup · Inst Constrain edge
Healthcare · Medical Devices
Sell if holding. Engine safety override at $6.25: Quality below floor (1.6 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.3/10 and A.R:R 1.9:1 is above the 1.5:1 BUY gate. Specifically: Below-average business quality; Below long-term trend.
AdaptHealth Corp. is a national home medical equipment and healthcare-at-home provider organized into four segments - Sleep Health, Respiratory Health, Diabetes Health and Wellness at Home - serving approximately 4.3 million patients annually across 48 states through roughly 640... Read more
Sell if holding. Engine safety override at $6.25: Quality below floor (1.6 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.3/10 and A.R:R 1.9:1 is above the 1.5:1 BUY gate. Specifically: Below-average business quality; Below long-term trend. Chart setup: Death cross but MACD improving, RSI 82. Score 5.3/10, moderate confidence.
Passes 8/9 gates (positive momentum, favorable risk/reward ratio, clean insider activity, no SEC red flags, news events none recent, earnings proximity 19d clear, semi cycle peak clear, materials cycle peak clear). Suitability: speculative.
Recent developments
updated 2026-10-15Recent Developments — AdaptHealth Corp.
Latest news
- NEWS Baird Maintains Outperform on AdaptHealth, Lowers Price Target to $9 — benzinga Sep 17, 2026 positive
- NEWS AdaptHealth Corp. Appoints Harriss T. Currie CFO, Effective Sept. 9, Succeeding Jason Clemens — benzinga Sep 8, 2026 neutral
- NEWS UBS Maintains Buy on AdaptHealth, Lowers Price Target to $10 — benzinga Aug 6, 2026 positive
- NEWS RBC Capital Maintains Outperform on AdaptHealth, Lowers Price Target to $8 — benzinga Aug 6, 2026 positive
- NEWS Truist Securities Maintains Buy on AdaptHealth, Lowers Price Target to $9 — benzinga Aug 5, 2026 positive
Generated 2026-10-15T11:47:12Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
3 floor-breakers
Technicals below the gate floor. Component breakdown shows what dragged the score down.static
Unprofitable operations — net margin -6.8%. Quality floor flags this regardless of sector context.static
No near-term catalyst priced in. Thesis progression will come from fundamentals grinding, not event reaction.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Engine safety override at $6.25: Quality below floor (1.6 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.3/10 and A.R:R 1.9:1 is above the 1.5:1 BUY gate. Specifically: Below-average business quality; Below long-term trend. Chart setup: Death cross but MACD improving, RSI 82. Prior stop was $5.83. Score 5.3/10, moderate confidence.
Take-profit target: $7.71 (+23.3% upside). Prior stop was $5.83. Stop-loss: $5.83.
Quality below floor (1.6 < 4.0); Value-trap signals (2/5): Margin compression (op margin 3.2%), Material insider selling (8 sells, 0.80% of cap).
AdaptHealth Corp. trades at a P/E of N/A (forward -50.2). TrendMatrix value score: 8.3/10. Verdict: Sell.
13 analysts cover AHCO with a consensus score of 4.3/5. Average price target: $9.
What does AdaptHealth Corp. do?AdaptHealth Corp. is a national home medical equipment and healthcare-at-home provider organized into four segments -...
AdaptHealth Corp. is a national home medical equipment and healthcare-at-home provider organized into four segments - Sleep Health, Respiratory Health, Diabetes Health and Wellness at Home - serving approximately 4.3 million patients annually across 48 states through roughly 640 locations. The company derives about 61% of net revenue from third-party private payors, with sleep therapy equipment and supplies alone contributing approximately 42% of 2025 net revenue and PAP resupply products contributing about 32%.